Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria - Wikidata - thesis-toulmin - TriplyDB

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

http://www.wikidata.org/entity/Q33281394

about

A review of malaria vaccine clinical projects based on the WHO rainbow table Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines Engineering the chloroplast targeted malarial vaccine antigens in Chlamydomonas starch granules Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Parasite burden and severity of malaria in Tanzanian children Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure Plasmodium immunomics.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques.Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C.Blood stage vaccines for Plasmodium falciparum: current status and the way forward.Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.Effects of age, hemoglobin type and parasite strain on IgG recognition of Plasmodium falciparum-infected erythrocytes in Malian children.Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens.Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates.Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission.Malaria vaccines and their potential role in the elimination of malaria.Malaria vaccines: a toy for travelers or a tool for eradication?Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142).Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria.N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine.Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West Africa.Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.Evaluation of recombinant Plasmodium knowlesi merozoite surface protein-1(33) for detection of human malaria.Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.Cryptosporidium parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15.

P2860

Q21034112-91CDB51A-C5C4-406F-A89F-3DAB3FAEA932 Q28484081-1BE0EBFC-918C-47F5-8DA9-82CD025C0639 Q28740432-E570623C-40D3-4CFF-9559-57C77CF57CD8 Q28744199-D9C6ACD3-75DA-4648-A9D1-EE45AB92C1E9 Q28749215-C2DB854C-85A2-4518-BE78-C3D257908E8D Q33380204-5E1B8FC3-5213-4B90-8FC0-37A6CC4DDD42 Q33380213-6AC2CEF1-7F49-49F8-BA03-D71BE3F8DF3E Q33394245-1D40B4F1-B9A5-4B3D-B558-FFDCE68B32D5 Q33434412-AA275D36-452E-4EF9-B5B2-B811981548CC Q33882158-6BCDD7F5-BEB5-4AC5-AEC6-CF2EC9CF118F Q33916707-407B8002-49C4-4FAA-84A8-34E19DC3CF93 Q34257253-4BB8645E-071A-48A0-8B43-C5ECD13D7FA9 Q34419934-B3B09FC7-0F59-445D-B3EB-39C69F168512 Q34441098-E7321ED2-349D-466B-B917-0A63FE409CFC Q34615872-197C4F45-33C1-4E24-AA7F-C7D85697035C Q34653470-CE91A3FD-B966-42F0-B125-DCAD66FACADD Q34663978-39D6DA6C-3FA2-4272-9A4E-6FC86A32E3EC Q35003931-5A20A323-407B-4F5B-A848-E9895D228A30 Q35017067-DAAEBC58-CC3D-4582-AB14-F6DC5F6AF7F0 Q35264640-3A17D07C-DA6A-47A3-A8D3-72DD9F69FFC4 Q35456892-EA3A42E7-7D9E-4FAE-B9D1-07C27E992A18 Q36368017-E470D689-F92E-490F-B5B1-14801BE29357 Q36477537-6A8A4483-1772-471B-A5E3-F3D07C497056 Q36639261-AA3D492B-3930-4072-A517-087664F1D569 Q36917011-8ABC9C04-517C-4AE1-95DE-3DD3AD7BF15E Q37018637-CDE04F86-BBAF-480D-A5AA-DE2FDE646233 Q37194780-7409A687-B261-4968-A507-6690CF9C38B4 Q37256085-879BD684-5100-42DB-8992-BF5B54BCA867 Q37264673-EDDE61B6-C66C-4CE7-839E-32A730E78604 Q37297549-23375C02-AE27-489E-8298-BB94427B91D8 Q37425845-8ED49636-20CD-487F-9004-D9A5DF299B4A Q37924616-5C5922F4-47ED-4182-BBF6-FCA85C8B9763 Q38159694-F3CE754E-C659-4228-B4B1-9B8434C3FE4D Q38942086-7393AA96-37AA-4152-ABB7-C1DD42E5430C Q40055186-8EA9443B-430B-490E-BA23-EE8187706A65 Q40474408-B6973D69-1627-4A87-BF62-06FE98068B56 Q41844553-6002DC98-C8A1-4363-AB39-18873544DC14 Q41985489-663EA5FB-ABC8-4FC9-81DA-31F428FAD105 Q42415030-CCE46701-4000-4484-894A-808ADF1BE8EA Q42571297-C31D6C97-F7C1-4F38-A771-30DCACCA5F62

P2860

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

http://www.wikidata.org/entity/Q33281394

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@ast

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@en

type

label

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@ast

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@en

prefLabel

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@ast

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@en

P1433

Q33281394-2BE95912-B123-4486-905A-A067DD61980E

P1476

Q33281394-0DD07274-AF56-4A71-95F9-A83F02F169A2

P2093

Q33281394-044E8662-E9F2-4552-AC5B-6E393A8E5F93

Q33281394-0B7143B0-592C-4BB1-83A9-E3617EB957B0

Q33281394-1806A108-8D0F-463C-9282-B85CA2D99853

Q33281394-43CCA430-1462-493C-AACA-A9CA1C6B3247

Q33281394-5B8BC56A-F8D3-44EB-9E02-6C29E9338EEC

Q33281394-5C51D2CC-7EA2-465F-AB82-5A91A9E9A560

Q33281394-6EFE747D-13A4-4C0E-9E4A-6CAB143117FB

Q33281394-7AECFC5E-FDB0-4A64-A799-BB84194433D8

Q33281394-7ECE9F5C-CE1C-402E-ADF7-5EDA2BDFD2B5

Q33281394-82F4540C-22F5-45D9-8802-91BDF39B108C

P2860

Q33281394-018446CC-E500-408A-AA4E-8F101D032947

Q33281394-055FDA2B-1BB3-4C2C-9FE3-30DE3D3DBD07

Q33281394-08D401A8-6E26-42E5-8AC3-0305244E6377

Q33281394-0DA16A44-48AA-41EE-9DEB-98C7A80C0184

Q33281394-0E271A63-3FA9-4F98-A02F-AB0037475508

Q33281394-18126C03-B9BA-465E-B591-7A289177D8DB

Q33281394-1B244E60-3C2D-41AF-8DA0-516BD18DD7E6

Q33281394-1D52FA25-2500-4985-B88E-E23EB79708DC

Q33281394-4E11F0AA-93BE-48E6-B3B1-E5A998BB1FFC

Q33281394-5766C614-F37B-4D31-B793-34E16BB0D0D9

P304

Q33281394-3E2D1F55-BB25-4740-8DAA-0F70431A3D96

P31

Q33281394-B0926FB5-C94C-4BC0-B5F3-CDCBF27CF7D1

P356

Q33281394-10B2CB41-2CF7-45A3-98E0-11125E294061

P433

Q33281394-7A44870F-112B-4B46-9494-0C02213FF6CA

P478

Q33281394-5731714D-78CB-4B40-B9BD-E3A976BD6F65

P50

Q33281394-3B2E6B07-736C-411F-85D2-71AC3449AEE6

Q33281394-445C2F55-A707-4CA1-9AEE-D83DF8E3CB57

Q33281394-5C254BA4-0D9E-448A-A7CE-CCA941CB26F9

Q33281394-803F2F0F-3E0C-4A35-B7FE-9435CF0E1F77

Q33281394-85E9FA7A-CEE9-4688-BAF5-AEA80D5512C8

P577

Q33281394-8EE2FD47-140B-4D6D-81A7-82AD3FF14BB5

P5875

Q33281394-3850C915-49C3-4892-84D0-5E7F198EB5D0

P698

Q33281394-60AAA4FA-B06C-447B-BA8A-74EBFA328056

P921

Q33281394-3744356C-21B9-43AE-A537-8E51A924D9DF

Q33281394-54EEFE70-A41A-4C7F-8642-60EF8FFB2EBA

P932

Q33281394-8B050AFF-8AD4-4511-B895-4F3F1155554B

P356

JOURNAL.PCTR.0020012

P1433

PLOS Clinical Trials

P1476

Phase 1 study of two merozoite ...... Plasmodium falciparum malaria

@en

P2093

Aaron P Miles

http://www.w3.org/2001/XMLSchema#string

Ababacar Diouf

http://www.w3.org/2001/XMLSchema#string

Andrew C Orcutt

http://www.w3.org/2001/XMLSchema#string

Anthony W Stowers

http://www.w3.org/2001/XMLSchema#string

Elissa Malkin

http://www.w3.org/2001/XMLSchema#string

Eveline Tierney

http://www.w3.org/2001/XMLSchema#string

Hong Zhou

http://www.w3.org/2001/XMLSchema#string

Lanling Zou

http://www.w3.org/2001/XMLSchema#string

Laura B Martin

http://www.w3.org/2001/XMLSchema#string

Michael Fay

http://www.w3.org/2001/XMLSchema#string

P2860

Production of the antimalarial drug precursor artemisinic acid in engineered yeast

Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.

Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.

Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria.

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.

Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds

Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic areas.

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

P304

e12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PCTR.0020012

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Louis H. Miller

Siddhartha Mahanty

P577

2007-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6407585

http://www.w3.org/2001/XMLSchema#string

P698

17415408

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

1847697

http://www.w3.org/2001/XMLSchema#string